April 25 (Reuters) - Canada's health department said on
Sunday the 1.5 million doses of the Astrazeneca Plc
COVID-19 vaccine imported from Emergent BioSolutions'
Baltimore facility were safe and met quality specifications.
The U.S. Food and Drug Administration (FDA) had stopped
AstraZeneca from using the facility earlier this month and
halted production of Johnson & Johnson's vaccine at the
plant as it began investigations into an error that led to
millions of doses of J&J's vaccine being ruined last month.
However, Health Canada said it reviewed test results of all
vaccine lots that came into the country and found them to be
safe.
J&J doses produced at the Baltimore, Maryland, site have not
entered the country, the regulator said, adding that vaccines
from the company anticipated to be imported next week were not
made at that facility.
(Reporting by Derek Francis in Bengaluru; editing by Diane
Craft)
Astrazeneca (AZN)
